No matter how cynical the overall market is Vaxcyte Inc (PCVX) performance over the last week is recorded 6.02%

On Monday, Vaxcyte Inc (NASDAQ: PCVX) was 3.57% up from the session before settling in for the closing price of $88.54. A 52-week range for PCVX has been $48.24 – $121.06.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

When this article was written, the company’s average yearly earnings per share was at 5.15%. With a float of $120.20 million, this company’s outstanding shares have now reached $124.64 million.

Let’s look at the performance matrix of the company that is accounted for 254 employees. In terms of profitability, gross margin is 2.95%, operating margin of -3662.28%, and the pretax margin is -3514.11%.

Vaxcyte Inc (PCVX) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vaxcyte Inc stocks. The insider ownership of Vaxcyte Inc is 3.56%, while institutional ownership is 107.23%. The most recent insider transaction that took place on Nov 18 ’24, was worth 686,518. In this transaction PRESIDENT AND CFO of this company sold 8,000 shares at a rate of $85.81, taking the stock ownership to the 109,491 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Officer proposed sale 8,000 for $86.50, making the entire transaction worth $692,000.

Vaxcyte Inc (PCVX) Performance Highlights and Predictions

Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.82 earnings per share (EPS) during the time that was less than consensus figure (set at -0.99) by -0.83. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 5.15% per share during the next fiscal year.

Vaxcyte Inc (NASDAQ: PCVX) Trading Performance Indicators

You can see what Vaxcyte Inc (PCVX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.88.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.68, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -4.69 in one year’s time.

Technical Analysis of Vaxcyte Inc (PCVX)

Vaxcyte Inc (NASDAQ: PCVX) saw its 5-day average volume 1.64 million, a positive change from its year-to-date volume of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 27.63%. Additionally, its Average True Range was 4.64.

During the past 100 days, Vaxcyte Inc’s (PCVX) raw stochastic average was set at 41.99%, which indicates a significant increase from 22.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.87% in the past 14 days, which was lower than the 60.57% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $107.44, while its 200-day Moving Average is $83.29. Nevertheless, the first resistance level for the watch stands at $92.88 in the near term. At $94.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $95.96. If the price goes on to break the first support level at $89.79, it is likely to go to the next support level at $87.88. Assuming the price breaks the second support level, the third support level stands at $86.71.

Vaxcyte Inc (NASDAQ: PCVX) Key Stats

There are 124,637K outstanding shares of the company, which has a market capitalization of 11.43 billion. As of now, sales total 0 K while income totals -402,270 K. Its latest quarter income was 0 K while its last quarter net income were -103,120 K.